ArticleERJ open research2025
The activin pathway in chronic thromboembolic pulmonary hypertension: a potential biomarker for residual pulmonary hypertension after endarterectomy.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review.Pulmonary circulation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is characterised by persistent pulmonary vascular obstruction due to unresolved thromboembolic lesions and distal pulmonary vascular remodelling. Despite the recognised role of the activin pathway in pulmonary vascular remodelling, its involvement in CTEPH remains insufficiently explored. This study aimed to investigate the presence of activin pathway components in CTEPH-related microvasculopathy and evaluate their potential as biomarkers. Methods: Plasma levels of activin pathway biomarkers and key inflammatory mediators were assessed in controls and operable CTEPH patients pre- and post-surgery. The study enrolled 69 patients (mean age 62±13 years, 51% male), among whom 29 exhibited residual pulmonary hypertension (PH) after surgery, and two died following post-endarterectomy (PEA). Results: CTEPH patients demonstrated elevated levels of activin-A, activin-B, FSTL3, C-X-C motif chemokine ligand 9 (CXCL9), β-nerve growth factor, C-reactive protein (CRP) and pro-brain natriuretic peptide (compared to controls). Pre-operative activin-A levels were associated with an increased risk of residual PH or mortality post-surgery (odds ratio 2.469, 95% CI 1.011-5.487; p=0.027), following adjustments for age, mean pulmonary arterial pressure before PEA, and CRP. Histological analysis of lung specimens from CTEPH patients revealed nuclear accumulation of phosphorylated Smad 2 and upregulation of inhibin-βA, inhibin-βB, activin receptor type IIB (ACTRIIB) and FSTL3 in muscularised pulmonary arterioles. Conclusions: These findings suggest a potential role for activin-A as a predictive biomarker for residual PH following pulmonary endarterectomy in CTEPH. Further investigation into the activin pathway may uncover therapeutic targets for managing CTEPH-associated vascular remodelling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.